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ABSTRACT The mesolimbic dopamine system has re-
cently been implicated in the long-term aversive consequences
of withdrawal from major drugs of abuse. In the present study
we sought to determine whether mesolimbic dopamine neu-
rons are involved in the neurobiologic mechanisms underlying
withdrawal from chronic cannabinoid exposure. Rats were
treated chronically with the major psychoactive ingredient of
hashish and marijuana, D9-tetrahydrocannabinol (D9-THC).
Administration of the cannabinoid antagonist SR 141716A
precipitated an intense behavioral withdrawal syndrome,
whereas abrupt D9-THC suspension failed to produce overt
signs of abstinence. In contrast, both groups showed a reduc-
tion in dopamine cells activity as indicated by extracellular
single unit recordings from antidromically identified meso-
accumbens dopamine neurons. The administration of D9-THC
to spontaneously withdrawn rats restored neuronal activity.
Conversely, SR 141716A produced a further decrease of
spontaneous activity in cannabinoid-treated although it was
ineffective in control rats. These data indicate that withdrawal
from chronic cannabinoid administration is associated with
reduced dopaminergic transmission in the limbic system,
similar to that observed with other addictive drugs; these
changes in neuronal plasticity may play a role in drug craving
and relapse into drug addiction.
Popular derivatives of the hemp plant (Cannabis sativa) such
as hashish and marijuana are the most abused substances
among illicit compounds currently available for recreational
use (1). Much of this popularity may stem from the fact that
socially they are widely tolerated and often perceived as
harmless and only mildly addictive (2). Probably because of
their long half-lives in the body (3, 4) it has been traditionally
difficult to demonstrate a well-defined withdrawal syndrome
that, in turn, is one of the qualifying elements in the recog-
nition and classification of drugs of abuse (5). Another factor
that may be viewed as important in the clarification of these
issues has been the absence of pharmacological tools (antag-
onists) appropriate for these investigations. Recently, how-
ever, SR 141716A, a compound with antagonistic properties
toward the central cannabinoid receptor (CB1), has been
described (6) and it has made possible to ascribe specific
effects to the stimulation of CB1 receptors. In line with this,
it has been shown that the blockade of chronic stimulation of
CB1 receptors with SR 141716A, precipitates a behavioral
withdrawal syndrome (7, 8) that is accompanied by a marked
elevation of corticotropin-releasing factor in the limbic system
(9). This effect, previously observed after withdrawal from
other abused substances, is thought to subserve the neuronal
mechanisms of stress and anxiety (10) that are part of the
negative emotional state common to withdrawal from drugs of
abuse.
The mesolimbic dopamine (DA) system, aside from its
recognized role in the acute rewarding effects of addictive
substances, has recently been implicated in the long-term
aversive consequences of spontaneous and drug-induced with-
drawal from major drugs of abuse such as ethanol, morphine
and cocaine (11, 12). Cannabinoids, although widely abused by
humans, are traditionally considered somewhat milder and less
addictive than other drugs of abuse. Nevertheless, they are
known to produce, upon cessation of chronic intake, a somatic
withdrawal syndrome, and when acutely administered, to
stimulate DA neuronal activity in the limbic system (13–15)
two effects recognized to be peculiar to major addictive drugs
(14, 16, 17).
More relevant to the issue of drug addiction is, however, the
involvement of the dopaminergic system in the chronic effects
of addictive drugs. In line with this, it was found that the
spontaneous activity of DA neurons of the meso-accumbens
pathway is reduced after withdrawal from chronic administra-
tion of ethanol (18), and morphine (19), and that the reduction
in their activity persists after somatic withdrawal has subsided
(12, 20). These findings are consistent with the idea that
mesolimbic DA participates in the long-term aversive conse-
quences of drug withdrawal, which may contribute to drug
seeking behavior and relapse into drug dependence.
We report here that chronic treatment with cannabinoid,
and subsequent withdrawal, results in a reduction in the
neuronal activity of the mesolimbic dopaminergic pathway
independent of somatic manifestations of abstinence.
METHODS
Subjects and Cannabinoid Treatment. Male Sprague–
Dawley albino rats (200–300 g) were used in all experiments.
All subjects were kept on a 12 hy12 h lightydark cycle with
food and water available ad libitum. Experimental protocols
were approved by the Ethical Committee at the University of
Cagliari and performed in strict accordance with the Euro-
pean Community regulations for the use of experimental
animals (CEE N°86/609). D9-Tetrahydrocannabinol (D9-
THC), in ethanol solution, was purchased from Research
Biochemicals International (Natick, MA); it was evaporated
immediately before use under argon gas and the residue was
emulsified in 1% Tween 80, then diluted in a saline solution.
SR 141716A was obtained through Sanofi Research (Paris)
and emulsified in 1% Tween 80, then diluted in a saline
solution. Drugs were administered i.p. in a volume of 3 ml
per kg of body weight. Animals assigned to the cannabinoid
withdrawal condition (n 5 20) received twice daily injections
of D9-THC (15 mgykg i.p.) for 6.5 days; a subgroup of these
animals (n 5 10) received SR 141716A (10 mgykg i.p.). 10
min after administration of SR 141716A, or its vehicle, rats
were placed singly in Plexiglass cages (30 3 25 3 45 cm) with
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standard rat litter on the f loor. Cages were located in a
sound-proof room for behavioral observation. Point-scoring
was performed by an observer blind to treatment placed
behind a one-way window. Cannabinoid withdrawal signs in
both spontaneous and SR 141716A-induced withdrawal were
evaluated with counted signs (total number of events over a
30 min period of time) such as scratching, wet dog shakes,
facial rubbing, and licking. Counted signs were subjected to
nonparametric statistical analysis (Mann–Whitney U test).
Electrophysiological Recording. Standard extracellular
recordings from antidromically identified ventral tegmental
area (VTA)-accumbens dopaminergic neurons were per-
formed as already described (18) with the exception that
gallamine triethiodide (20 mgykg i.v.) was used as a muscle
relaxant instead of d-tubocurarine. The choice of locally
anesthetized rats is based on the fact that general anesthesia
(chloral hydrate, ketamine) has been shown to alter the
effect of various cannabinoids on the electrophysiological
response of mesolimbic dopaminergic neurons (15, 21).
Brief ly, subjects were temporarily anesthetized with halo-
thaneyroom air inhalation anesthesia and the femoral vein
was cannulated for i.v. administration of pharmacological
agents. The trachea was then exposed and incised to allow
tracheal intubation with a Tef lon catheter for artificial
respiration. Gallamine triethiodide (20 mgykg i.v.) was ad-
ministered i.v. and once muscular paralysis was obtained the
rat was placed in a stereotaxic apparatus (Kopf Instruments,
Tujunga, CA) and the tracheal catheter connected with a
mechanical rodent ventilator (7025 Stoelting) set to deliver
90 strokesymin (3 mlystroke). Incision and pressure points
were infiltrated with a 2% solution of xylocaine. Body
temperature was maintained constant at 38 6 1°C by means
of an electrically controlled heating pad. Thereafter, rats
were prepared as follows: the scalp was retracted and two
burr holes were drilled: one for the placement of a recording
electrode above the VTA (AP 1.8–2.0 from lambda; L
0.2–0.6 from midline) (22), and the other to introduce a
Formvar coated stainless-steel bipolar electrode for anti-
dromic identification in the nucleus accumbens (AP 8.8 from
lambda; L 1.6 from midline; V 7.1 from dura matter) (22, 23).
Stimuli consisting of monophasic rectangular pulses (0.1–2.0
mA; 0.1–0.5 msec; 0.8 Hz) were generated. Stimulating
current was monitored on the oscilloscope. Dopaminergic
neurons were identified according to well established elec-
trophysiological characteristics [i.e., (ı`) Action potentials
with biphasic or triphasic waveforms greater than 2.5 msec
in duration. (ı`ı`) A typically slow spontaneous firing rate. (ı`ı`ı`)
Occurrence of single and burst spontaneous firing pattern.
(ı`v) Long antidromic latency] and by antidromic activation
from the nucleus accumbens including collision of an anti-
dromically elicited spike with spontaneously occurring ac-
tion potentials (23). The extracellular neuronal signal from
single neurons was amplified (Neurolog System, Digitimer,
Welwyn Garden City, U.K.) and displayed on a digital
oscilloscope (Philips pm 3305) before storage on magnetic
tape for off-line analysis of the data. Firing rate and pattern
analysis were performed as already described (24). The basal
firing rate was recorded for 5 min. The number of sponta-
neously active DA neurons was determined by passing the
electrode eight times through four different areas within the
VTA, according to the method proposed by Bunney and
Grace (25). Coordinates of tracks were 2.0 and 2.2 mm
anterior to lambda and 0.3 and 0.5 mm lateral to midline
(22). The electrode was lowered twice in each spot, whereas
the total number of active cells were counted and divided by
the number of passes to obtain cellsytrack index. The
FIG. 1. Mean 6 SEM of summed behavioral cannabinoid-withdrawal scores observed for a total of 30-min observation period before
electrophysiological experiments. Control (vehicle-treated n 5 18). P-W rats (n 5 10) treated for 6.5 days with D9-THC and challenged with the
cannabinoid antagonist SR141716A (10 mgykg i.p.). S-W rats (n 5 10) treated for 6.5 days with D9-THC and challenged with vehicle. Control and
S-W groups are not statistically different (Mann–Whitney U test, U: 79–84.5, P . 0.2). Conversely, P-W rats show a marked behavioral withdrawal
syndrome whose score is statistically significant (Mann–Whitney U test, U: 69.5, P , 0.001) when compared with the S-W group.
Table 1. Various electrophysiological parameters recorded from D9-THC withdrawn, both spontaneous (S-W) and
induced (P-W), and vehicle-treated (CTRL) rats
No. of cells Cellsytrack Firing rate, Hz Burst rate, burstysec Spikesyburst
CTRL 142 0.99 6 0.06 3.2 6 0.07 0.33 6 0.02 3.26 6 0.05
S-W 96 1.2 6 0.08 2.05 6 0.07** 0.14 6 0.02** 2.62 6 0.07*
P-W 90 1.12 6 0.05 1.68 6 0.04** 0.13 6 0.01** 2.15 6 0.09**
Cellsytrack, number of cells responding to antidromic identification from nucleus accumbens divided by the number of
tracks; firing rate, number of spikes per second, Hz; burst rate, number of bursts averaged for 1 sec; spikesyburst, number of
action potentials per each burst. Statistical analysis (ANOVA 1 Newman–Keuls’ test) revealed that D9-THC withdrawn rats
showed a reduced spontaneous activity in terms of firing rate [F(2,35) 5 16.53, **P , 0.01], burst firing [F(2,35) 5 7.06; **P ,
0.01] and spikesyburst [F(2,35) 5 8.28; *P , 0.05, **P , 0.01].
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statistical significance of the data was evaluated by using
one-way ANOVA 1 Newman-Keuls’ test.
RESULTS
Rats treated twice daily for 6.5 days at the dose of 15 mgykg
i.p., 24 h after the last cannabinoid administration were
evaluated behaviorally (Fig. 1). Pharmacologically induced
withdrawal (P-W), precipitated by administration of the CB1
antagonist SR 141716A (10 mgykg i.p.; n 5 10), produced an
intense behavioral manifestation similar to previous observa-
tions (7, 8), whereas spontaneous (S-W) (n 5 10) failed to
produce overt signs of withdrawal. In fact, when compared
with control rats (Fig. 1) S-W rats were found not statistically
different (P . 0.05 Mann–Whitney U test). After the 30 min
behavioral observation, rats were prepared for standard ex-
tracellular recording experiments. VTA DA neurons were
antidromically identified from the nucleus accumbens (22, 23)
and were found to have altered basal electrophysiological
characteristics in respect to corresponding vehicle-treated
controls (Table 1). In particular, firing rates (as depicted in
Figs. 2, 3, 4), burst firing and spikesyburst of individual neurons
were found to be below control levels in both groups (Table 1).
Intravenous administration of D9-THC (0.25–1 mgykg) to a
subgroup of S-W rats (n 5 4) restored the declining dopami-
nergic electrical activity (Fig. 4). Percentage increase was
159.04 6 23.73 (n 5 4, P , 0.01, Student’s t test) when
compared with pre-drug baseline. However, if compared with
the mean firing rate of control rats (table 1), the increase in
firing rate was found to be not significantly different (65 6
23.64%; n 5 4, P . 0.05 Student’s t test for unpaired
observations). Conversely, the administration of SR 141716A,
to another subgroup of S-W rats (n 5 3), resulted in a marked
and long-lasting reduction of DA neuronal activity (Fig. 5A).
Percentage decrease in firing rate produced by the cannabi-
noid antagonist SR 141716A was 49.1 6 8.7% when compared
with pre-drug baseline (P , 0.01, Student’s t test). In contrast,
FIG. 2. Spontaneous activity of antidromically identified VTA-accumbens DA neurons encountered in a rat belonging to the CTRL (Top) S-W
(Middle) and P-W (Bottom) groups, respectively. Each histogram represents the neuronal activity of a single neuron. Note the difference in
spontaneous activity in the three groups. Recordings were obtained 24 h after last D9-THC (S-W) and vehicle administration (CTRL) and 2–3 h
after SR 141716A administration (P-W).
FIG. 3. Individual firing rates of antidromically identified VTA-
accumbens DA neurons recorded from S-W, P-W and Control groups.
Each circle represents the mean firing rate of 5-min recording. Note
the difference in distribution and the trend in silencing from Control
toward cannabinoid withdrawal conditions. Horizontal bars indicate
the mean activity as reported in Table 1.
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administration of SR 141716A (n 5 5), at the same dosage, to
control (vehicle-treated) rats did not alter (0.6 6 0.14%; P .
0.05 Student’s t test for unpaired observations vs. pre-drug
baseline) firing rate of mesolimbic DA neurons (Fig. 5B).
DISCUSSION
Collectively, these results indicate that withdrawal from
chronic treatment with D9-THC induces changes in neuronal
plasticity that can be further unmasked by administration of
the specific cannabinoid antagonist SR 141716A. Indeed, rats
undergoing S-W from D9-THC do not show a somatic mani-
festation of the withdrawal syndrome as observed in their SR
141716-treated (P-W) counterparts. Nevertheless, both groups
(SR 141716A-treated and untreated) showed a decline in the
dopaminergic functioning of the mesolimbic system of similar
magnitude (Table 1). This result indicates that reduction in
electrophysiological activity of DA neurons antidromically
identified as projecting to the nucleus accumbens, has no
relationship with behavioral manifestations of cannabinoid
withdrawal. Interestingly, this lack of relationship has been
already documented for two major addictive drugs such as
ethanol (12, 20) and morphine (12). Further, D9-THC admin-
istration to rats not exposed to the antagonist resulted in
increased firing rates comparable to those observed in controls
(15), whereas SR 141716A administration resulted in an
abrupt reduction in the already abated electrophysiological
activity of DA neurons (Fig. 5A). Because SR 141716A was
ineffective when administered to control rats, these results
indicate that DA neurons of the limbic system, after chronic
D9-THC, are driven in their spontaneous activity by the
exogenous cannabinoid. In addition, the lack of effect of SR
141716A in control rats (see also ref. 15, 27), suggests that
endogenous cannabinoids are unlikely to participate in the
modulation of electrophysiological activity of DA neurons of
the mesolimbic system. Increased firing rate after i.v. D9-THC
in S-W rats, together with the abrupt reduction in mesolimbic
DA neuronal activity observed after administration of the
cannabinoid antagonist SR 141716A in S-W rats but not in
controls, suggest that these changes are ascribable to with-
drawal from chronic D9-THC.
These changes in the dopaminergic functioning of the limbic
system, affecting specifically firing rate, burst firing and spikesy
burst of these units, with no alteration in the cellsytrack index,
suggest that VTA DA neurons projecting to the nucleus
accumbens are reduced in their spontaneous activity but not
FIG. 4. Example of the effect of cumulative
doses of the cannabinoid agonist D9-THC ad-
ministered i.v. at arrows on an antidromically
identified VTA-accumbens DA neuron recorded
from a S-W rat. Numbers above arrows indicate
dosage expressed in mgykg. Recording was per-
formed 24 h after last D9-THC administration.
FIG. 5. (A) Effect of the cannabinoid antagonist SR
141716A administered i.v. at arrows on an antidromi-
cally identified VTA-accumbens DA neuron recorded
from a rat belonging to the S-W group. Recording was
performed 24 h after last D9-THC administration. (B)
The figure shows the failure of i.v. SR 141716A, admin-
istered at arrows, in altering the spontaneous neuronal
activity of an antidromically identified VTA-accumbens
DA neuron recorded from a rat belonging to the
Control group. Recording was performed 24 h after last
vehicle administration. Numbers above arrows indicate
dosage expressed in mgykg.
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affected by depolarization blockade (26). Thus they appear to
be more refractory to intrinsic and extrinsic depolarizing
stimuli. However, irrespective of the mechanism underlying
the reduction in dopaminergic neuronal function, the present
results indicate that withdrawal from chronic cannabinoid
exposure induces subtle changes in the mesolimbic dopami-
nergic system that can be further evidenced by administration
of SR 141716A, per se ineffective (15, 27). These changes,
indexed by neurophysiological and pharmacological evidences,
are: (i) reminiscent of those recently reported for other, more
harmful, substances such as ethanol and opiates (12, 18, 28).
Indeed, if compared, the reduction in DA neuronal activity is
qualitatively, but not quantitatively, similar in the three with-
drawal syndromes, being morphine.cannabinoids.ethanol,
respectively. (ii) Consistent with the idea that lessening dopa-
minergic functioning in the limbic system may substantially
contribute to the neurobiological basis of the subjective aver-
sive consequences of drug withdrawal (dysphoria) rather than
somatic aspects of it (29).
These data are part of a large and still growing body of
evidence that indicates that chronic administration of addictive
drugs results in major changes in the physiology (11, 12),
biochemistry (30, 31) and even anatomy (32) of the mesolimbic
DA system. These changes, in turn, may render the mesolimbic
DA pathway more vulnerable and thus facilitate relapse into
a drug dependent state. From another viewpoint, these data
indicate that withdrawal from chronic cannabinoid exposure
results in neurobiological alterations not dissimilar from those
observed after protracted administration with substances, such
as ethanol and opiates, which are widely considered to be more
harmful.
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